Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor… Read more
Oric Pharmaceuticals Inc (ORIC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.062x
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has a cash flow conversion efficiency ratio of -0.062x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.11 Million) by net assets ($406.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oric Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Oric Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oric Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanxi Zhangze Electric Power Co Ltd
SHE:000767
|
0.120x |
|
Omeros Corporation
NASDAQ:OMER
|
0.084x |
|
Yibin Tianyuan Group Co Ltd
SHE:002386
|
0.021x |
|
Purecycle Technologies Holdings Corp
NASDAQ:PCT
|
-0.564x |
|
MASTERBRAND INC. DL-001
F:D55
|
N/A |
|
Amalgamated Bank
NASDAQ:AMAL
|
0.047x |
|
Chongqing Taiji Industry Group Co Ltd
SHG:600129
|
0.015x |
|
Servyou Software Group Co Ltd
SHG:603171
|
N/A |
Annual Cash Flow Conversion Efficiency for Oric Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Oric Pharmaceuticals Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $243.12 Million | $-112.66 Million | -0.463x | -21.19% |
| 2023-12-31 | $224.09 Million | $-85.69 Million | -0.382x | -13.15% |
| 2022-12-31 | $222.35 Million | $-75.14 Million | -0.338x | -54.94% |
| 2021-12-31 | $272.98 Million | $-59.54 Million | -0.218x | -39.62% |
| 2020-12-31 | $289.78 Million | $-45.27 Million | -0.156x | +41.60% |
| 2019-12-31 | $87.97 Million | $-23.53 Million | -0.267x | -183.32% |
| 2018-12-31 | $-64.43 Million | $-20.68 Million | 0.321x | +139.65% |
| 2017-12-31 | $25.73 Million | $-20.83 Million | -0.810x | -- |